Articles tagged with Memory B Cells
Researchers at La Jolla Institute for Immunology discovered that FluMist can trigger an immune response directly in nasal tissue, training immune cells to recognize and fight influenza virus infection. This response stays in the upper airways and cannot be detected via blood samples.
Researchers have found that COVID vaccines can train immune cells to remember the SARS-CoV-2 virus and protect against severe infection for years afterward. However, the continued spread of disease has scientists taking a closer look at how the immune system builds up immune memory over time.
Researchers at Penn State College of Medicine discovered a new function of antibody-making B cells in response to flu infection. These cells produce a key signaling molecule called interleukin-1 beta, which is necessary for developing a robust immune response and forming optimal germinal centers.
Researchers found that B cells guide CD8 T cells to mount lasting defenses after vaccination, but their absence weakens immunity. The discovery could lead to new strategies to enhance vaccine effectiveness for those with compromised immune systems.
A study of 113 healthcare workers found that COVID-19 mRNA vaccination induces long-lasting antibody and memory B-cell responses, even in those previously exposed to the virus. The research team also discovered an association between higher levels of specific antibodies and increased risk of breakthrough infections.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers developed a microfluidic chip that can measure memory B cells' binding affinity to flu virus, helping track immunity. The device, Shear Activated Cell Sorting (SACS), can compare how well cells bind to original and new variants.
Researchers found impaired PD-1 activity can significantly reduce antibody diversity and quality in memory B cells. This may explain the increased rates of infection reported in patients with cancer receiving checkpoint inhibitor therapy.
A team of researchers at UMC Utrecht has identified 29 novel antibodies against the bacterium Klebsiella pneumoniae, an important cause of drug-resistant infections. The antibodies were found to interact with antigens on the bacterial surface and some act synergistically to neutralize the pathogen.
Researchers at La Jolla Institute for Immunology have discovered immune cells, such as tissue resident memory cells, in the upper airway that can fight infections and build long-term immunity. These findings may lead to better vaccines and a deeper understanding of immunity against respiratory pathogens.
Researchers found that T cells and memory B cells provide durable protection against symptomatic SARS-CoV-2 infection, with levels attainable after two doses of mRNA vaccination. The study suggests a two-dose vaccination regimen for children against COVID-19.
Researchers found that vaccinated B cell-deficient individuals have a robust T cell response to SARS-CoV-2, despite lack of anti-spike antibodies, resulting in markedly reduced rates of hospitalization and severe COVID-19. This study provides reassuring evidence for immunocompromised patients to get vaccinated.
Researchers found that a breakthrough infection builds upon existing memory B cell pool and introduces random mutations that prepare antibodies for new variants. Broad neutralizing antibodies can neutralize all tested Omicron variants.
Researchers found a quantitative difference in B cell response following vaccination between young and older adults, with younger adults mounting a stronger clonal response and older adults having more activated B cells. This study provides insights into the age-related differences in B cell vaccine response and may lead to the develop...
Scientists from Osaka University found a shorter Rubicon isoform that boosts autophagy in B cells, leading to increased memory B cell generation and enhanced recall responses. This discovery sheds light on manipulating B cell memory and resolving conflicting findings about Rubicon's functions.
Scientists have found that lung-resident memory B cells, critical for pulmonary immunity, require interferon-gamma produced by T follicular helper cells to differentiate. These long-lived immune cells migrate to the lungs from draining lymph nodes and lie in wait to react quickly to future infections.
A new subset of memory B cells, marked by the FcRL5 receptor protein, has been identified as a predictor of long-lived antibody responses to influenza vaccination. These effector memory B cells can be detected seven days after immunization and correlate with vaccine antibody responses months later.
Researchers identified a type of immune cell called age-associated B cells as key drivers of lupus disease. Targeting these cells in a mouse model reduced disease progression, suggesting a potential new therapy for lupus patients.
A new study reveals that long-lived germinal centers, which can last for six months, are maintained by a dynamic balance between founder B cells and newly introduced naive B cells. The research provides insights into the workings of these microscopic training grounds and could inform future vaccine design.
A recent study finds that exposure to proteins in common foods, vaccines, bacteria, and viruses can prime the immune system to attack SARS-CoV-2, potentially providing protection against COVID-19. The study's findings suggest that individuals with a history of exposure to these agents may be less susceptible to severe illness.
Scientists locate highly effective memory B cells in the lungs, which can boost the efficacy of vaccines used to protect against viral respiratory diseases. The discovery suggests a promising avenue for increasing vaccine effectiveness.
Researchers discovered that memory B cells produce non-specific antibodies to combat virus mutants, working alongside phagocytes to screen for variants. This mechanism may offer protection against SARS-CoV2 and HIV variants, and could influence vaccine development.
Researchers found that people who had COVID-19 and then got vaccinated generated an immune response more specific to fighting viral infections, producing a broader antibody response. This hybrid immunity also produced a cellular immune response called Th1 response, which is antiviral.
Researchers tracked antibody response to COVID-19 vaccination and found that antibodies improve in quality for months after vaccination. Even low levels of antibodies provide some protection as long as the virus doesn't change.
A new study reveals that mRNA vaccines activate a type of helper cell called T follicular helper cells, which assist in creating powerful antibodies and drive the development of immune memory. This strong response helps prevent severe disease and death, even against highly mutated variants like omicron.
A new study found that infection-fighting B cells retain better memory of the coronavirus spike protein in patients who recover from less-severe cases of COVID-19 than those recovering from severe cases. This hints at subtle differences in the quality of immune response based on COVID-19 severity.
Researchers found that CD4+ T lymphocytes — immune system cells — produced by people who received COVID-19 vaccines persisted at high levels six months after vaccination, with a significant response against the delta variant. The study also showed that vaccine-elicited fighters recognize and help attack coronavirus delta variant.
A new study reveals that memory T helper cells can work with memory B cells to effectively defend the body against chronic viruses. This finding has direct relevance to developing new vaccines for HIV and hepatitis C, as it suggests a more sustained immune response.
A study of young Swedish adults found that over one in four had SARS-CoV-2-specific antibodies, but fewer had measurable levels of memory B and T cells compared to other age groups. The researchers will continue to study long COVID and vaccination effects on immunity.
A study by University of Minnesota Medical School researchers found that fully vaccinated individuals with a previous SARS-CoV-2 infection have a stronger immune response, producing more memory B cells. This increased immune response may reduce the risk of breakthrough infections and potentially fewer doses needed for booster shots.
Researchers at Karolinska Institutet discovered that B cells choose between cell fates to balance acute and memory responses. This understanding could optimize vaccines against viruses or other pathogens.
Researchers found that protective B cell responses remain stable over time, but do not recognize emerging SARS-CoV-2 variants from Brazil and South Africa. A large proportion of neutralizing antibodies generated by long-lasting B cells only target conserved epitopes.
A new study by Tomohiro Kurosaki at Osaka University reveals that Bach2 expression and reduced mTORC1 activity are necessary for activated B cells to become memory B cells, a type of white blood cell that sticks around for years and provides rapid responses to re-infection. This understanding can help develop efficient vaccines.
Researchers have identified a new target for creating flavivirus vaccines by targeting specific locations on the virus. This approach aims to remove memory B cells from the vaccination equation and avoid antibody-dependent enhancement of infection, which can result in more severe symptoms.
A study published in mBio found that past infections with coronaviruses, including the common cold, can induce long-lasting immunity against COVID-19. The research also showed cross-reactivity between memory B cells that target SARS-CoV-2 and those targeting other betacoronaviruses.
Researchers at WashU Medicine developed an approach to assess vaccine activation in lymph nodes, showing that the flu vaccine can elicit antibodies protecting against a broad range of flu viruses. The findings could aid in designing an improved flu vaccine providing protection against old and new strains.
Researchers identified an enhanced immune response to the H5N1 influenza virus in a two-dose vaccination trial. The findings suggest that this approach could lead to the development of a universal flu vaccine targeting multiple strains.
Researchers identified an antibody, called S309, that can inhibit related coronaviruses, including the cause of COVID-19. The antibody targets a protein structure critical to the coronaviruses' ability to infect cells, neutralizing them and potentially providing a treatment for severe illness.
Researchers have detailed the role of T-bet, a key transcription factor, in transforming B cells into antibody-secreting cells. The study found that T-bet acts through a distinct mechanism, repressing inflammatory genes in B cells to facilitate their differentiation.
A new study by MD Anderson Cancer Center suggests that certain B cells with unique characteristics can predict which patients are most likely to respond to immunotherapy for metastatic melanoma and kidney cancer. The researchers found that activated B cells with specific phenotypes were associated with a better response to treatment.
A recent study published in Nature Immunology reveals that lung-resident memory B cells can provide more effective immunity against influenza infections. These cells are able to respond quickly and produce antibodies after a second infection, suggesting they play a crucial role in respiratory virus immunity.
Scientists at Garvan Institute of Medical Research have identified a new micro-organ within the immune system that helps fight reinfection fast. The structure, named SPFs, is strategically positioned to detect infection early and contains immune cells gathering to mount a rapid response.
Researchers analyzed blood samples from 35 healthy adults and found a marked increase in antibody-producing B cells and circulating T follicular helper cells after vaccination. The study's findings suggest that intranasal vaccination might be more effective than injections, with implications for ideal inoculation routes.
Researchers developed an assay to detect autoantibodies present in rheumatoid arthritis patients, finding that memory B cells secrete these molecules. The study suggests targeting these immune system cells could lead to a cure for the disease.
Researchers found that exposure to malaria's blood stage inhibits the formation of protective immune cells and antibodies. This discovery highlights the need for a vaccine that targets both stages of infection to effectively prevent malaria.
Activated B cells play a crucial role in the formation of immune memory, with some cells persisting for months after initial exposure. The study reveals that while plasmablasts dominate early responses to infections or vaccinations, activated B cells take center stage later on.
A research group at Osaka University has clarified the molecular mechanism behind inducing germinal-center B cells to differentiate into memory B cells, a crucial step in creating effective vaccines. This breakthrough reveals that lower-affinity maturation of antigens is key to memory B cell differentiation.
A new study found that HIV-infected individuals have impaired affinity maturation of memory B cells, resulting in low frequencies of somatic hypermutation and poor HIV-neutralizing capacity. This immune dysfunction contributes to the ineffective antibody response against HIV.
A licensed technology measures anti-HLA antibody secretion from memory B cells, improving kidney transplant efficiency and preventing rejection. Researchers found high-risk patients using this technique, which complements existing antibody measurement methods.
A new TSRI study explains how booster shots prompt immune memory to improve, a crucial step toward longer-lasting vaccines. The research demonstrates how immune cells evolve and adapt to recognize viruses, leading to more diverse and effective antibody responses.
Researchers have identified the role of the STAT3 gene in immune system memory, revealing how it directs chemical messenger molecules to various destinations. This discovery sheds light on a rare immunodeficiency disorder and may lead to improved vaccines and treatments.
Researchers found that T-bet and RORα proteins enforce specific classes of memory B cells, which can produce antibodies against various infections. This discovery opens the way for developing vaccines that induce long-term immunity towards desired antibody classes.
A study found that infants colonized by E. coli bacteria early in life have a higher number of memory B cells. Healthy gut bacteria play a crucial role in immune system development and preventing allergies.
Researchers from the Walter and Eliza Hall Institute have discovered a new cell survival protein, Mcl-1, essential for creating and maintaining B cell memory. This finding contradicts existing theories and has implications for cancer treatment and autoimmune disease.
A new study found that re-treating rheumatoid arthritis (RA) patients who failed initial treatment with rituximab after six months significantly improves clinical responses, including complete remission and EULAR responses. This strategy provides hope for patients classified as non-responders.
Scientists have developed a new technology to isolate dozens of HIV-specific antibodies from a single individual, allowing for the first time to study natural antibody-mediated HIV neutralization. This breakthrough may prove important in understanding how effective HIV-neutralizing antibodies arise during infection.
Exhausted B cells hinder HIV-infected individuals' ability to clear the virus from their bodies. Researchers found that these cells produce low-quality antibodies, making it challenging to develop an effective vaccine.
Researchers from UT Knoxville have made a groundbreaking discovery about memory B cells, which are crucial for fighting off influenza infections. By analyzing where these cells reside after an infection, scientists can develop more effective vaccines that target specific strains and subtypes of the flu virus.
A study published in Immunology Letters describes new ways of inducing immune responses through selective B cell priming, suggesting a potential approach to rational vaccine design. This discovery could have significant practical implications for vaccination development.
Researchers found that bacterial infections can activate self-reactive B cells with significant affinity, driving them to mature into harmful memory B cells. This activation is facilitated by the cooperation of autoantigens, innate immunity, and T cells.